Application of the screening and indirect cohort methods to evaluate the effectiveness of pneumococcal vaccination program in adults 75 years and older in Taiwan
Abstract Background The Taiwanese national 23-valent pneumococcal polysaccharide
vaccine (PPV23) program in adults≥ 75 years of age and the 13-valent pneumococcal …
vaccine (PPV23) program in adults≥ 75 years of age and the 13-valent pneumococcal …
Have changing pneumococcal vaccination programmes impacted disease in Ontario?
GH Lim, AE Wormsbecker, A McGeer, DR Pillai… - Vaccine, 2013 - Elsevier
BACKGROUND: Publicly funded infant 7-valent pneumococcal conjugate vaccine (PCV7)
was introduced in Ontario, Canada in 2005 and was replaced by 10-and 13-valent vaccines …
was introduced in Ontario, Canada in 2005 and was replaced by 10-and 13-valent vaccines …
Effectiveness of 23-valent pneumococcal polysaccharide vaccine in adults aged 60 years and over in the Region of Madrid, Spain, 2008–2011
MAG Rodriguez, MAO Gavin, L Garcia-Comas… - …, 2014 - eurosurveillance.org
Invasive pneumococcal disease (IPD) is a notifiable disease in the Region of Madrid. The 23-
valent pneumococcal polysaccharide vaccine (PPV23) is recommended for children and …
valent pneumococcal polysaccharide vaccine (PPV23) is recommended for children and …
[HTML][HTML] Distribution of serotypes causing invasive pneumococcal disease in older adults from high-income countries and impact of pediatric and adult vaccination …
LR Grant, MPE Slack, C Theilacker, J Vojicic, S Dion… - Vaccine, 2023 - Elsevier
Background Neither indirect protection through use of 13-valent and 10-valent
pneumococcal conjugate vaccines (PCV13 and PCV10) in pediatric National Immunization …
pneumococcal conjugate vaccines (PCV13 and PCV10) in pediatric National Immunization …
Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease among 948,263 individuals≥ 65 years of age: a Danish …
KF Nielsen, LB Nielsen, FK Lomholt… - European Journal of …, 2022 - Springer
This study aimed to estimate the effectiveness of the 23-valent pneumococcal
polysaccharide vaccine (PPV23) against invasive pneumococcal disease (IPD) among …
polysaccharide vaccine (PPV23) against invasive pneumococcal disease (IPD) among …
[HTML][HTML] The estimated impact of the 5-year national vaccination program on the trend of 23-valent pneumococcal polysaccharide vaccine vaccination rates in the …
T Naito, M Suzuki, K Fujibayashi, A Kanazawa… - Journal of Infection and …, 2020 - Elsevier
Pneumonia is the third most common cause of death in Japan. Low vaccination rates are
thought to be related to low levels of public subsidy. Since 2014, the Japanese government …
thought to be related to low levels of public subsidy. Since 2014, the Japanese government …
Vaccination coverage and associated factors for receipt of the 23-valent pneumococcal polysaccharide vaccine in Taiwan: a nation-wide community-based study
CH Chen, MS Wu, IC Wu - Medicine, 2018 - journals.lww.com
Vaccination coverage and associated factors for receipt of t... : Medicine Vaccination coverage
and associated factors for receipt of the 23-valent pneumococcal polysaccharide vaccine in …
and associated factors for receipt of the 23-valent pneumococcal polysaccharide vaccine in …
Early impact of 13-valent pneumococcal conjugate vaccine use on invasive pneumococcal disease among adults with and without underlying medical conditions …
SS Ahmed, T Pondo, W Xing, L McGee… - Clinical Infectious …, 2020 - academic.oup.com
Background The 13-valent pneumococcal vaccine (PCV13) was introduced for US children
in 2010 and for immunocompromised adults≥ 19 years old in series with the 23-valent …
in 2010 and for immunocompromised adults≥ 19 years old in series with the 23-valent …
Limited indirect effects of an infant pneumococcal vaccination program in an aging population
M van der Linden, M Imöhl, S Perniciaro - PloS one, 2019 - journals.plos.org
Background A general recommendation for adult pneumococcal vaccination with 23-valent
polysaccharide vaccine (PPV23) for adults 60 and older has been in place in Germany since …
polysaccharide vaccine (PPV23) for adults 60 and older has been in place in Germany since …
Epidemiology of invasive pneumococcal disease among high-risk adults since the introduction of pneumococcal conjugate vaccine for children
RD Muhammad, R Oza-Frank, E Zell… - Clinical Infectious …, 2013 - academic.oup.com
Background. Certain chronic diseases increase risk for invasive pneumococcal disease
(IPD) and are indications for receipt of 23-valent pneumococcal polysaccharide vaccine …
(IPD) and are indications for receipt of 23-valent pneumococcal polysaccharide vaccine …